Shanghai MicroPort EP MedTech Announces First Case of the Clinical Trial Of FlashPoint™ Renal Artery RF Ablation System
On 12 December 2013, Shanghai MicroPort EP MedTech Co., Ltd., a subsidiary of MicroPort Group, is pleased to announce that it has completed the first case of the clinical trial of FlashPoint™ Renal Artery RF Ablation System in which the case was performed under the affiliation with Guangxi Medical University by Professor Lang Li. FlashPoint™ is independently developed by Shanghai MicroPort EP MedTech. "This is a prospective, multicenter, randomized controlled clinical trial and the successful completion of the first clinical trial case suggests that it has formally entered into clinical research stage," said Dr. Yiyong Sun, the President of Shanghai MicroPort EP MedTech. "MicroPort EP MedTech will be further working on the development of the product and provide better options for patients with treatment-resistant hypertension."
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.